BACKGROUND: Patients with heterozygous familial hypercholesterolemia (FH) patients often have difficultly achieving National Cholesterol Education Program (NCEP) goals. Herein we present an evaluation of a centrally located, nationwide treatment support program that remotely attempted to educate and guide FH patients by monitoring their serum low-density lipoprotein (LDL) cholesterol levels and giving appropriate treatment recommendations through mail contact. All subjects were FH patients registered with the Make Early Diagnosis to Prevent Early Deaths (MEDPED) program. METHODS: In this descriptive evaluation, we compared self-reported lipid levels in 386 FH patients participating in our treatment support program with 295 non-participants who had responded to questionnaires. Participants were recruited into the treatment support program if they had not reached their LDL cholesterol goal after at least 1 year of follow-up and were unable to receive specialized lipid care due to location. RESULTS: Participants who continued for a longer term in the treatment support program achieved greater total cholesterol reductions (14%) than the comparison group (7%, P=.004). Reductions in total and LDL cholesterol were highly correlated with more aggressive use of statin medications (P <.0001). CONCLUSIONS: These results demonstrate the potential benefits and limitations of a centralized program operating remotely to encourage appropriate treatment of severe hypercholesterolemia.
BACKGROUND:Patients with heterozygous familial hypercholesterolemia (FH) patients often have difficultly achieving National Cholesterol Education Program (NCEP) goals. Herein we present an evaluation of a centrally located, nationwide treatment support program that remotely attempted to educate and guide FHpatients by monitoring their serum low-density lipoprotein (LDL) cholesterol levels and giving appropriate treatment recommendations through mail contact. All subjects were FHpatients registered with the Make Early Diagnosis to Prevent Early Deaths (MEDPED) program. METHODS: In this descriptive evaluation, we compared self-reported lipid levels in 386 FHpatients participating in our treatment support program with 295 non-participants who had responded to questionnaires. Participants were recruited into the treatment support program if they had not reached their LDL cholesterol goal after at least 1 year of follow-up and were unable to receive specialized lipid care due to location. RESULTS:Participants who continued for a longer term in the treatment support program achieved greater total cholesterol reductions (14%) than the comparison group (7%, P=.004). Reductions in total and LDL cholesterol were highly correlated with more aggressive use of statin medications (P <.0001). CONCLUSIONS: These results demonstrate the potential benefits and limitations of a centralized program operating remotely to encourage appropriate treatment of severe hypercholesterolemia.
Authors: Joshua W Knowles; Emily C O'Brien; Karen Greendale; Katherine Wilemon; Jacques Genest; Laurence S Sperling; William A Neal; Daniel J Rader; Muin J Khoury Journal: Am Heart J Date: 2014-09-16 Impact factor: 4.749
Authors: Muin J Khoury; Michael S Bowen; Wylie Burke; Ralph J Coates; Nicole F Dowling; James P Evans; Michele Reyes; Jeannette St Pierre Journal: Am J Prev Med Date: 2011-04 Impact factor: 5.043
Authors: Richard Ceska; Gustavs Latkovskis; Marat V Ezhov; Tomas Freiberger; Katarina Lalic; Olena Mitchenko; Gyorgy Paragh; Zaneta Petrulioniene; Belma Pojskic; Katarina Raslova; Aleksandr B Shek; Branislav Vohnout; Tereza Altschmiedova; Veronika Todorovova Journal: Curr Atheroscler Rep Date: 2019-06-22 Impact factor: 5.113
Authors: Laney K Jones; Stephanie Tilberry; Christina Gregor; Lauren H Yaeger; Yirui Hu; Amy C Sturm; Terry L Seaton; Thomas J Waltz; Alanna K Rahm; Anne Goldberg; Ross C Brownson; Samuel S Gidding; Marc S Williams; Michael R Gionfriddo Journal: Implement Sci Date: 2021-04-13 Impact factor: 7.327